No­var­tis just signed a $1.6B buy­out pact with a lead play­er in an emerg­ing an­ti-in­flam­ma­to­ry field

The ex­ec­u­tive crew at IFM has just racked up their sec­ond block­buster-sized biotech sale in less than two years.

Not long af­ter Bris­tol-My­ers Squibb stepped up with $300 mil­lion in cash to ink a $2.3 bil­lion-plus pact on the on­col­o­gy ap­pli­ca­tions of their work on NL­RP3 in the sum­mer of 2017, phar­ma gi­ant No­var­tis has lined up rights to the flip side of that coin, pay­ing IFM $310 mil­lion up­front in a $1.6 bil­lion bid to demon­strate what NL­RP3 can do on the an­ti-in­flam­ma­to­ry side of things.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.